Opinion

Do OS, QoL and Pain Management Data Favour the Use of TTFields For the Treatment of LAPAC? – ESMO

ESMO/LinkedIn

Jul 30, 2025, 14:46

Do OS, QoL and Pain Management Data Favour the Use of TTFields For the Treatment of LAPAC? – ESMO

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“Quality of Life and Pain Management data from the PANOVA-3 trial adds to efficacy results of combining Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel as a potential new option of care for patients with locally advanced Pancreatic Adenocarcinoma (LAPAC).

Do Overall Survival, Quality of Life and pain management data taken together really favour the use of TTFields for the treatment of LAPAC?

Read the analysis by Angela Lamarca in the ESMO Daily Reporter to learn more about these results and their implications for patients.”

More posts featuring Tumor Treating Fields.

Angela Lamarca ESMO ESMO - European Society for Medical Oncology ESMO Daily Reporter European Society for Medical Oncology PANOVA-3 trial Tumor Treating Fields

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth